Related Experiment Video
Updated: Jun 4, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Severe hepatic necrosis associated with methyldopa
Canadian Family Physician Medecin De Famille Canadien
|February 4, 2011
Summary
Family physicians must monitor patients on methyldopa for potential liver toxicity. Overlooking this risk, as seen in a case report, can lead to severe liver failure and hepatic coma.
Area of Science:
- Internal Medicine
- Pharmacology
Background:
- Methyldopa is a common antihypertensive medication.
- Its potential for causing liver toxicity is often underestimated.
- Liver injury from methyldopa can be severe and life-threatening.
Purpose of the Study:
- To highlight the risk of methyldopa-induced liver toxicity.
- To emphasize the importance of vigilant monitoring in patients receiving methyldopa.
- To present a case illustrating severe hepatotoxicity.
Main Methods:
- A case report of a 45-year-old female patient with severe hypertension treated with methyldopa.
- Clinical observation of liver function tests and patient's condition.
- Liver biopsy to assess hepatic damage.
- Follow-up assessment of liver recovery.
Main Results:
- The patient developed abnormal liver tests after 7.5 months of methyldopa treatment.
- She progressed to liver failure and hepatic coma.
- Liver biopsy revealed severe hepatic necrosis.
- The patient slowly recovered after methyldopa discontinuation.
Conclusions:
- Methyldopa can cause severe, potentially fatal, liver toxicity.
- Regular monitoring for liver function is crucial for patients on methyldopa.
- Early detection and discontinuation of methyldopa can prevent severe outcomes.
Related Concept Videos
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...